Key takeaways
- Inulin is a fermentable fiber. Its source, chain-length distribution and accompanying ingredients matter
- A defined native chicory inulin preparation has an EU stool-frequency food claim at 12 g/day; it is not approval to treat every cause of constipation (claim conditions)
- Positive trials have commercial support, small samples or other design limits. This review does not establish a dependable independent treatment benefit (Micka; Puhlmann; Watson)
- Inulin can increase gas. More fermentation or more bifidobacteria does not itself establish less pain or better functioning (acute MRI study; microbiome study)
- Inulin, short-chain FOS, oligofructose and blends differ; one preparation cannot automatically inherit another’s results (ingredient distinctions; blend trial)
Inulin is a fermentable fiber with some positive bowel trials and a narrowly defined European food claim. Results vary by preparation and population. Major positive adult studies have commercial support; small samples, carryover and outcome-analysis limits also matter. A blend’s symptom signal and an acute reduction in MRI gas do not establish inulin-alone IBS treatment. This review does not establish a dependable general supplement regimen for constipation or IBS, and its financial screen is not evidence that inulin cannot help (EU claim; adult trial; IBS blend; MRI experiment).
Contents
Evidence summary · What it is · Forms and grades · How it works · Hype versus evidence · Benefits by claim · What works · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources
Evidence summary
Grades concern the exact claim and the evidence eligible after funding checks. A commercially supported result is described accurately but does not establish this article's independent benefit verdict. A declaration of no competing interests does not resolve an unidentified product supplier or missing financing information.
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Defined native chicory inulin increases stool frequency | Favorable EFSA assessment and EU-authorized food claim | EFSA 2015; EU regulation | Manufacturer application; underlying studies not an independently funded evidence set | High confidence in regulatory fact; independent clinical estimate insufficient |
| Improves adult constipation | Positive short crossover trials; selection, carryover and analysis limits | Micka 2017; Puhlmann 2025 | BENEO or Sensus funding and company authors | Insufficient independent evidence; excluded from independent benefit basis |
| Improves bowel function in everyone | Mixed small studies; population-specific review | Watson 2019; AHRQ 2025 | Sensus-funded trials; publicly commissioned review does not erase underlying conflicts | Universal claim unsupported |
| Treats constipation-predominant IBS | 34-person, 50:50 inulin/oligofructose blend; symptom-severity change signal | Akçalı 2025 | Unnamed private supplier; cash and purchase/donation unresolved | Preliminary blend evidence; stool-form, overall QOL-change and depression-change tests null |
| Improves children’s constipation | Small agave trial in severe cerebral palsy; hard-stool comparison favorable, frequency not established | García Contreras 2020 | No external funding declared; researcher furnished named products, payment terms unknown | Insufficient for routine pediatric use |
| Repairs an unhealthy microbiome | Microbial changes in a commercially sponsored cohort | Vandeputte 2017 | BENEO funding and employees | Insufficient for “repair” or disease prevention |
| Fermentation can increase colonic gas | Acute MRI experiment | Gunn 2022 | Public grants; indirect ties and procurement gap | Moderate for physiology |
What it is
Inulin is a family of fructose-rich carbohydrates, rather than one uniform molecule. Human digestive enzymes do not readily break its characteristic linkages, allowing it to reach the colon and become a microbial substrate. Chicory roots are a commercial source; other plant-derived preparations have different structures and chain-length distributions. The FDA's ingredient assessment distinguishes these materials by source, processing and chemical properties. FDA science review
This review concerns oral food and supplement ingredients. It does not treat a spoonful of purified powder as equivalent to a serving of vegetables, a complete nutritional formula or a drug. The clinical question is whether adding a specified preparation improves a meaningful digestive outcome compared with an appropriate control.
Forms and grades
| Preparation | What distinguishes it | Why the distinction matters |
|---|---|---|
| Native chicory inulin | A distribution of shorter and longer fructans, with small amounts of sugars | The EU claim defines a mean degree of polymerization of at least 9 (legal composition) |
| Long-chain or high-performance inulin | Processing enriches longer chains | It is not automatically dose-equivalent to native inulin or a short-chain preparation |
| Oligofructose | Shorter fructans, including material obtained by hydrolyzing inulin | It overlaps chemically with the inulin family but has its own trial and regulatory record |
| Sucrose-derived short-chain FOS | Manufactured short fructans with a more restricted composition | Research on this preparation cannot be reassigned to every inulin powder |
| Agave-derived preparations | A different plant source; structure and specification require checking | “Agave inulin” on a study label does not establish equivalence to the EU-defined chicory ingredient |
| Inulin plus other fibers or microbes | A combination intervention | Any improvement belongs initially to the tested combination |
Degree of polymerization, or DP, describes chain length. Definitions and commercial mixtures overlap, so an arbitrary cutoff should not be used to turn every published “inulin-type fructan” trial into an inulin-alone trial. FDA ingredient distinctions, EU compositional conditions
Useful label information includes the source, actual grams of ingredient and fiber, other fermentable ingredients, and whether a named formulation matches the one studied. “Clinical grade,” “organic” and a trademark do not answer the clinical question. This review does not establish a superior brand.
How it works
Inulin supplies material that intestinal microbes can use. Fermentation produces metabolites and gas; possible effects on bacterial mass and stool properties provide a rationale for bowel studies. It is soluble but generally much less viscous than gel-forming fibers, so sharing the word “fiber” does not mean sharing every physical effect. FDA science review
A stool-sample change can show a microbial response without demonstrating that a person feels better. In Gunn’s IBS experiment, adding psyllium reduced MRI gas after inulin without establishing significant pain or bloating relief. Patient outcomes require their own controlled assessment (microbial analysis; human MRI results).
Hype versus evidence
“Prebiotic” does not identify a patient’s need or an effective personalized regimen. The microbiome analysis found associations rather than a validated stool-test threshold for treatment selection (original analysis).
“Approved in Europe” needs its full conditions. Native chicory inulin has a defined stool-frequency food claim. The EU refused a different Frutalose oligofructose claim because the submitted evidence did not establish an effect under the proposed conditions. That is neither a blanket no-effect verdict nor a reason to transfer the native-inulin claim to every neighboring preparation (native inulin authorization; Frutalose decision).
Academic affiliation does not settle who paid. The adult bowel studies include ingredient-business funding and company employees. Blinding or a stated absence of sponsor influence is relevant to validity but does not remove that financial relationship (Micka disclosure; Puhlmann declarations; Watson declarations).
Short selected studies do not characterize uncommon allergy, prolonged use or every special population and medicine combination. Puhlmann reported possible gas, bloating and cramps; one food-associated allergy report cannot supply an incidence estimate (trial harms; case report).
Benefits by claim
Adult constipation and low stool frequency Insufficient independent evidence
Micka enrolled 54 volunteers; the primary per-protocol report concerned 44. It found median stool frequency of four versus three weekly bowel movements with 12 g/day native chicory inulin and placebo. BENEO sponsored the work and employed two authors. The full original paper remains only partly accessible here; original indexed Methods and disclosures plus the abstract support this account. The registry was first posted in September 2015 after study completion in May 2012 (original abstract; indexed original report; registration record).
Puhlmann randomized 40 adults and reported 39 in the abstract. The Sensus-funded crossover used 12 g/day Frutafit HD, including three days at 6 g/day. Its controlled change estimate was an additional 0.53 weekly defecations; Table 1 explicitly flags the associated p-value as biased by an intervention–period interaction. Carryover and later unblinded analysis limit interpretation. Stool consistency did not differ significantly. Quality-of-life and symptom point estimates favored inulin, but the crossover’s controlled mean differences were smaller than the paper’s cited minimum important differences; statistically positive results do not establish that those average differences were clinically important. An exploratory first-period analysis found larger frequency and quality-of-life differences, but was not the full crossover comparison. This qualifies the signal without erasing it (original Table 1, Figure 4 and limitations).
These trials do not establish dependable sustained treatment for every cause of constipation or every inulin product. They concern selected participants and short periods; frequency, stool consistency, symptoms and quality of life are distinct outcomes (Micka; Puhlmann).
Routine use when bowel function is already normal Insufficient independent benefit
AHRQ’s 2025 report evaluated people without bowel dysfunction. Its inulin analysis found no clear stool-frequency advantage, so it does not answer treatment of chronic constipation. The related 2026 publication describes the review’s methods and government contract. Neither review applied this article’s industry-exclusion rule to all underlying trials; their pooled evidence is contextual rather than a purified independent estimate (AHRQ inulin results; original methods and declarations).
Watson’s two Sensus-funded trials excluded diagnosed constipation. Ten participants completed one trial and twenty the other. Frequency improved in the first but not the second, whose baseline bowel frequency often exceeded the intended range. The overall pooled frequency result was null; a low-frequency subgroup was favorable after an outlier exclusion. That exploratory subgroup does not make the entire second trial positive or establish chronic-constipation treatment (original Methods, tables and Results).
“More bowel movements” is not automatically a useful goal for a person who already passes comfortable stools normally.
Constipation-predominant IBS Insufficient
Akçalı randomized 34 adults to a 9.2 g/day 50:50 inulin/oligofructose blend or placebo for eight weeks. The symptom-severity change comparison favored the blend, while stool-form comparisons were null. Changes in overall IBS quality of life and depression did not show significant group–time interactions, despite some favorable within-group or final-group tests. Participants were blinded but researchers were not; the registry was posted after trial completion. Cash support and the unnamed private supplier’s payment terms remain unresolved. This is preliminary blend evidence, not an isolated-inulin treatment or confirmed mood benefit (original Tables 3, 5–6; registry dates and outcomes).
Gunn’s 19-completer acute IBS study found that adding psyllium reduced the MRI gas response to a 20 g inulin challenge. It did not establish significant overall pain or bloating relief or a lasting clinical regimen (original human outcomes).
A useful IBS trial needs a prespecified symptom responder outcome and enough follow-up to establish whether benefit outweighs discomfort. Fermentation measurements cannot substitute for that test.
Children's constipation Insufficient
The agave-inulin trial included 49 children with severe cerebral palsy and constipation; 37 completed, leaving ten in the prebiotic arm and seven on placebo. It found a favorable controlled hard-stool comparison but no established prebiotic frequency benefit. The main researcher furnished the products, including Ingredion agave inulin and maltodextrin; purchase or donation terms were not reported. A small specialized trial does not establish routine use in otherwise healthy children (original Methods and Table 3).
The population, formulation and care needs are too specific to turn this into an over-the-counter pediatric dosing recommendation.
Microbiome repair and broader disease claims Insufficient
Vandeputte analyzed 42 participants from Micka’s cohort, rather than a new independent clinical replication. The BENEO-sponsored analysis changed selected bacterial groups without a significant overall change in measured volatile-metabolite profiles, although one individual volatile compound increased. Microbe–symptom associations did not establish causality, disease prevention or a validated stool-test treatment threshold (original results and disclosures).
The digestive studies discussed here do not establish barrier repair, SIBO eradication, IBD treatment, cancer prevention or lasting recovery after antibiotics. Their measured outcomes and populations do not answer those claims. This is a focused review, not proof that every study of every inulin mixture has been identified. Oligofructose-enriched mixtures are considered separately in this series’ FOS review (adult constipation outcomes; microbiome outcomes; acute IBS outcomes).
What works and what does not
| Claim | Verdict | Notes |
|---|---|---|
| Adds a fermentable fiber to a food or supplement | Supported as an ingredient property | Product composition determines the amount |
| A defined native chicory ingredient can carry a stool-frequency claim in the EU | Supported as a legal fact | Conditions are specific; the authority's standard differs from this funding screen |
| Independently established constipation treatment | Not established in the audited evidence | Positive commercial trials remain relevant context |
| Reliably improves all IBS symptoms | Not established | Small blend study and mechanistic gas experiments do not establish this |
| More bifidobacteria proves better health | Unsupported inference | A biomarker needs a validated relationship to patient benefit |
| Every inulin/FOS/agave preparation works identically | Unsupported | Source, chain lengths, processing and mixtures differ |
| Funding proves a study result is false | Incorrect | Conflicts and methodological validity are separate questions |
Risks and side effects
| Aspect | Finding | Source |
|---|---|---|
| Gas and bloating | Inulin increased MRI gas; coadministered psyllium reduced it without established overall pain/bloating relief | Human MRI experiment |
| Tolerance at a given dose | 26 healthy adults in single breakfast challenges; mostly mild symptoms, more after 10 g oligofructose. Full methods and funding not recovered | Bonnema 2010 original abstract |
| Allergy | A food-associated anaphylaxis case implicated an inulin–protein compound; a case report cannot estimate frequency | Franck 2005 |
| Persistent or alarming symptoms | Constipation with bleeding, constant abdominal pain, vomiting or inability to pass gas needs prompt medical assessment | NIDDK warning signs |
| Long-term and special-population safety | The small, selected trials do not settle pregnancy, breastfeeding, serious illness or uncommon adverse effects | Evidence gap in the trials reviewed above |
The allergy abstract concerns reactions to specific foods in one woman with an artichoke-allergy history. It suggests an inulin–protein compound; it does not estimate risk or establish that everyone with pollen/artichoke sensitivity reacts to every inulin preparation (original case abstract).
Safety: Breathing difficulty, throat swelling or collapse after a food or supplement requires emergency care (anaphylaxis guidance). Severe pain, persistent vomiting, bleeding or inability to pass gas warrants prompt assessment; do not dismiss these as a prebiotic “working” (constipation warning signs).
Interactions
| Substance or condition | Mechanism or concern | Severity/status | Source |
|---|---|---|---|
| Psyllium | Reduced MRI gas after an acute inulin challenge | No established overall pain/bloating relief or long-term regimen | Gunn 2022 |
| Medicines that contribute to constipation | Symptoms may have a medication-related cause that adding inulin does not address | Clinical assessment issue, not a demonstrated direct chemical interaction | NIDDK causes |
| Oral medicines generally | Ingredient-specific pharmacokinetic information was insufficient in this review | Unknown; do not infer a safe universal spacing interval | No comprehensive inulin-specific interaction trial identified |
| Known immediate reaction to an inulin-containing product | Re-exposure could pose an allergy risk | Potentially serious; product and allergen need assessment | Franck case report |
This table is not an exhaustive interaction database. The reviewed papers do not establish that all medicines should be separated from inulin by a fixed number of hours, nor that inulin changes every medicine's absorption. Product-specific ingredients and the medicine's own instructions matter. A person taking medicines should have the actual formulation assessed by a clinician or pharmacist rather than apply a generic fiber rule.
Who should avoid unsupervised use
Persistent unexplained bowel symptoms and the warning signs above need assessment, rather than progressively larger unsupervised fiber doses (NIDDK warning signs). A previous immediate reaction to the product warrants allergy advice before re-exposure (NHS prevention guidance).
Pregnancy, breastfeeding, childhood, severe gastrointestinal disease and complex medical treatment warrant individualized assessment because the evidence reviewed here does not establish a general supplement regimen for those situations. That evidence gap does not amount to a claim that ordinary inulin-containing foods are universally unsafe.
Dosage and how to take
These are descriptions of research or legal claim conditions, not instructions for personal use. A studied dose does not establish an effective or safe dose for another preparation or population.
| Use case | Studied dose | Duration | Notes |
|---|---|---|---|
| Selected low-frequency adults | 12 g/day native chicory ingredient | Four weeks per crossover period | 54 enrolled, 44 per-protocol; BENEO-funded, retrospectively registered (Micka; registry) |
| Selected healthy low-frequency adults | 10 g/day; first three days at 5 g/day | Five weeks per period | Mixed results; diagnosed constipation excluded, Sensus-funded (Watson) |
| Functional constipation | 12 g/day; first three days at 6 g/day | Four weeks per period | Sensus-funded; carryover and analysis limitations (Puhlmann) |
| IBS-C blend | 9.2 g/day of a 50:50 inulin/oligofructose mixture | Eight weeks | Combination, not isolated inulin; researcher unblinded, retrospectively registered (Akçalı; registry) |
| Children with cerebral palsy and constipation | 4 g/day agave ingredient | 28 days | 37 completers; specialized small trial, not pediatric self-treatment instructions (García Contreras) |
| Acute IBS MRI experiment | 20 g inulin, alone or with 20 g psyllium | Single challenges | Mechanistic protocol, not a long-term symptom regimen (Gunn) |
NIDDK's general constipation advice favors a gradual change in dietary fiber and an appropriate fluid intake, with individual health circumstances considered. It does not prescribe this particular supplement or establish that adding more inulin is always better. NIDDK dietary guidance
Animal and in vitro evidence excluded from conclusions
Gunn’s laboratory fermentation experiments are mechanistic context, separate from the human MRI challenge and symptom outcomes. They do not establish treatment efficacy (original Methods and Discussion).
No animal study is used to establish a human benefit or a human harm rate in this article. This is important in both directions: an animal mechanism suggesting barrier protection would not prove treatment, and an inflammatory signal in an experimental model would not by itself prove that ordinary human intake causes disease.
Independent funding tracing
Research funding at a glance
28 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Who pays and who profits
The commercial interests include ingredient manufacturers, supplement and food brands, distributors and their investors or cooperative members. Their incentives include selling fiber ingredients and helping customers make attractive food claims. That is an analysis of an ordinary business incentive, not an allegation of misconduct.
BENEO is a division of the Südzucker group, whose parent is based in Mannheim, Germany. Its chicory-fiber operations include Belgium and Chile; the location of an international group does not identify where an individual retail batch was produced. Group structure, manufacturer's production disclosure
Südzucker’s displayed shareholder snapshot lists SZVG own/trust-held shares at 64.93%, Austrian investors through Zucker Invest at 10.24%, and free float at 24.83%. A separate effective ownership date is not given. These are disclosed holdings, not proof that a shareholder controlled any trial result (official shareholder disclosure).
Sensus is part of the Dutch Royal Cosun cooperative and now presents its business as Cosun Ingredients. The legacy news index dates the transition 1 July 2026; the current company announcement, dated 30 June, describes July 1 as the effective date. Its listed headquarters and production locations are Dutch. Grower ownership remains a commercial interest, not clinical independence (Cosun identity; locations; dated announcement record).
Cosun also reported that Dutch government agreements signed in December 2025 reserved up to €105 million for energy reduction and production modernization. That is a separate industrial-support relationship; it is not evidence that the government financed an inulin clinical trial or that the full amount had been paid. Cosun's February 2026 disclosure
Money map

The diagram shows selected documented relationships. The linked details below also retain unreported procurement and author-finance limits. Ownership percentages are the company’s displayed snapshot, whose separate effective date is not supplied.
Documented relationships:
- SZVG in Germany → 64.93% own/trust-held shares → Südzucker in Germany (share disclosure)
- Zucker Invest in Austria → 10.24% displayed holding → Südzucker (share disclosure)
- Südzucker → BENEO division → Belgian and Chilean chicory-fiber operations (group structure; production locations)
- BENEO → study funding and company authors → Micka and same-cohort Vandeputte research (Micka original indexed disclosure; Vandeputte declarations)
- Royal Cosun, a Dutch agricultural cooperative → Sensus, now presented as Cosun Ingredients (corporate identity; transition announcement)
- Sensus → trial financing and company authors → Watson and Puhlmann research (Watson declarations; Puhlmann declarations)
- UK and Mexican public research bodies → declared support → Gunn’s MRI study; separate food/pharmaceutical author ties and procurement limits remain (original declarations)
- Dutch government → up to €105 million reserved under industrial energy agreements → Cosun; not established trial funding or disbursement (original February disclosure)
How this changes the verdict
Manufacturer funding does not prove an incorrect result. However, it disqualifies the outcome from the independent benefit basis used here. The same rule applies to favorable, null and unfavorable studies, including manufacturer-donated products or other in-kind research support even when the cash funder is public. An arm’s-length purchase is not itself sponsorship. When procurement terms cannot be established, they remain unknown.
EFSA found a cause-and-effect relationship for the specified food claim across heterogeneous trials, often with stool frequency as a secondary outcome. It said the conclusion could be reached without one proprietary study, although that study informed the conditions of use. Neither this nor EU-budget agency status proves that the remaining studies were industry-free; complete older-trial finance and procurement remain unresolved (original relevant assessment).
The research is concentrated in European ingredient businesses and European trial settings, with smaller studies elsewhere. Nationality is not a quality grade; concentration matters because repeated papers from the same sponsor or cohort provide less independent corroboration than they may appear to.
Regulatory status
European Union
The EU permits the defined native chicory inulin food claim at 12 g/day, with the specified composition including mean DP of at least 9. It concerns normal bowel function through increased stool frequency, not IBS, SIBO or cancer treatment. The initial five-year BENEO restriction began in January 2016 and does not remain exclusive in 2026 (original regulation and annex).
United States
FDA's current dietary-fiber FAQ includes inulin and inulin-type fructans among ingredients for which it intends to exercise labeling enforcement discretion pending rulemaking. The agency's physiological assessment includes mineral-absorption evidence; this is not a finding that every inulin supplement treats constipation or IBS. FDA FAQ, FDA science assessment
A product's lawful sale, food-label status and evidence for a clinical claim are separate questions. Rules also vary by jurisdiction and formulation; these two regulatory summaries do not cover every country.
Frequently asked questions
Is inulin the same as FOS?
These are related, partly overlapping fructans with different chain distributions and processing. Identify hydrolyzed oligofructose, sucrose-derived short-chain FOS and any blend explicitly; the tested specification matters (FDA ingredient distinctions).
Why call the independent evidence insufficient when Europe permits a claim?
The EU assessment accepts a specified stool-frequency claim; this review separately excludes commercial support from its independent benefit basis. Funding does not prove a result false. The favorable assessment and the methodological/financial limits of individual studies must both be retained (EFSA assessment; original trial limitations).
Does more gas mean inulin is helping?
No. In the human MRI experiment, reducing gas did not establish significant overall pain or bloating relief. Fermentation alone is not a treatment endpoint, and substantial discomfort should not be dismissed as “detox” (original human outcomes).
Can a microbiome test tell me whether I need it?
The microbial study did not validate a stool-test threshold for selecting an effective inulin regimen. Its bacterial changes and symptom associations did not establish a causal treatment target (original analysis).
Should inulin replace treatment for constipation or IBS?
The reviewed studies do not establish a general replacement for constipation or IBS care. Results concern selected participants and specified preparations; the doses above describe research, not instructions to change treatment. Persistent or alarming symptoms need assessment (adult trial; IBS blend; warning signs).
Sources and funding notes
The scorecard records relationships identified in the sources actually read. Tiers 1–4 mean no relevant stake identified in those records, indirect relationships, an interested party and direct commercial research support or involvement; U means unresolved provenance. These are provisional editorial labels, not a complete ownership, procurement or personal-conflict certificate. Credibility A–D describes accountability and source incentives for the specified use, not clinical certainty. A corporate page may accurately document its own identity without establishing independent efficacy. Reported lack of conflicts does not resolve every unreported relationship.
| Source | Funding or revenue and country | Tier / credibility for this use | Accuracy incentive and remaining limitation |
|---|---|---|---|
| Micka 2017 original report | BENEO sponsor/two employees; contract-research authors; Germany | 4 / C | Original abstract and indexed Methods/disclosure only; full tables/attrition/finance partly unavailable; 54 enrolled/44 per-protocol, retrospective registration |
| Vandeputte 2017 | BENEO funds plus Belgian public fellowships; company employees; Belgium/Germany | 4 / C | Accessible methods; same clinical cohort is not new replication |
| Watson 2019 | Sensus funded trials/statistics; UK public/charitable infrastructure also acknowledged; UK/Netherlands | 4 / C | Reports both positive and null trials; maker relationship remains |
| Puhlmann 2025 | Sensus funding; current/former employees; Netherlands/Ireland/Denmark | 4 / C | Carryover-biased frequency analysis; later unblinded analysis; stool consistency null; controlled QOL/symptom point estimates below cited important-difference thresholds |
| Akçalı 2025 | Turkish academic/hospital affiliations; no interests declared; unnamed private supplier | U / B provisional | Participant-only blinding and retrospective registration; cash/payment unknown; blend symptom signal but overall QOL/depression change tests null |
| García Contreras 2020 | Mexico; no external funds/COI declared; researcher supplied named Ingredion/Biogaia materials | U / B provisional | 49 included/37 completed; controlled hard-stool signal, frequency not established; purchase/donation terms unknown |
| Gunn 2022 | UK/Mexican public grants; food/pharma author ties; material-payment terms unknown | 2 provisional / B | Objective acute MRI; reduced gas does not establish pain/bloating relief or long-term treatment |
| Bonnema 2010 | US academic authors plus Cargill regulatory/scientific-affairs author | 4 / C | Original abstract/partial affiliations only; full cash/procurement/methods not recovered; no chronic safe ceiling |
| Franck 2005 | Nancy university hospital, France; funding/supply/COI unavailable in accessible abstract | U / B provisional | Single food-associated case; original abstract/title page only, not full immunologic-method or finance clearance; no incidence |
| AHRQ 2025 results | US publicly commissioned Brown review | 1 provisional at review level / A for report scope | Normal bowel function; inulin-frequency analysis null; all underlying commercial/unknown trial finances not purified or traced |
| Balk 2026 report of the review | AHRQ contract; US HHS/USDA sponsors; US/Australian authors; no conflicts reported | 1 provisionally at review level / B | Prespecified synthesis; disclosures are self-reported and pooled studies need separate checks |
| EFSA 2015 opinion | EU-budget agency, Parma; BENEO-Orafti application via Belgium | 1 institutionally; mixed underlying evidence / A for assessment record | Specified claim; heterogeneous trials, often secondary outcome; panel-personal interests and all older trial finances not fully audited |
| EU Regulation 2015/2314 | EU institutions and public budget; EU jurisdiction | 1 / A for law | Authoritative legal text; not a separately funded trial |
| EU Regulation 2023/1141 | EU institutions; manufacturer claim application | 1 for legal record / A | Documents a different preparation's refused claim; cannot substitute for trial appraisal |
| FDA 2018 science review | US public agency; agency-wide user fees disclosed below | 2 institutionally / A for chemistry and regulatory reasoning | Transparent review; manufacturer petitions and underlying studies retain their own interests |
| FDA current fiber FAQ | US federal regulatory publication | 2 institutionally / A for legal-policy scope | Direct agency statement; no individual clinical recommendation |
| NIDDK constipation symptoms | NIH public health information; United States | 1 provisionally / A for general safety context | Expert review and public mandate; page dated 2018, no named author conflict ledger |
| NIDDK dietary advice | NIH; United States | 1 provisionally / A for general context | Public-facing guidance; not inulin-specific efficacy evidence |
| Südzucker structure | Publicly listed producer group; Germany | 4 / C for corporate identity | Investor accountability; commercial self-description |
| Südzucker shareholding page | Producer investor relations; Germany, with Austrian shareholder link | 4 / C for disclosed holdings | Named percentages; underlying snapshot date not separately supplied |
| BENEO production disclosure | Ingredient maker; Germany/Belgium, Chilean manufacturing | 4 / C for locations, D for marketing | Direct knowledge of operations; feed/human health promotion excluded |
| Cosun corporate identity | Agricultural cooperative; Netherlands | 4 / C for organization | Member accountability; promotional content and live member count not audited |
| Sensus locations | Cosun ingredient business; Netherlands | 4 / C for location/name | Primary business record; no outcome validation |
| Sensus transition announcement record | Seller-operated Netherlands business publication | 4 / C for dated announcement | Legacy index: 1 July 2026; current issuer story: 30 June 2026, effective 1 July; no clinical validation |
| Cosun February 2026 disclosure | Cooperative issuer; Netherlands | 4 / C for announced industrial support | Primary self-report; reserved funds are not verified disbursement or trial financing |
| EFSA institutional funding FAQ | EU agency; Italy/EU | 1 / A for institutional facts | Official budget/HQ description; not a panel-member conflict audit |
| FDA user-fee explanation | US regulatory agency | 2 / A for its funding system | Public statutory framework; fee existence does not prove influence on this fiber decision |
| NIDDK budget information | NIH federal appropriations; United States | 1 / A for institutional funding | Public budget documentation; no claim that all academic collaborators are conflict-free |
These are source-specific checks, not a comprehensive audit of every investigator, donor, shareholder or supplier. Agency budget and academic affiliation are not automatic clinical endorsements; FDA user fees do not identify a payment for this inulin decision, and EFSA’s public budget does not make an applicant’s studies independent. Unreported amounts, original product-payment terms, retail-batch manufacturing and historical author relationships remain unknown.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
